Clinical Advisors

ViaCyte’s clinical advisors help guide the Company’s scientific and clinical initiatives in stem cell therapy.

Orville G. Kolterman, M.D.

Orville G. Kolterman, M.D.

Chief Medical Officer, Whole Biome Inc.; former Senior Vice President & Chief Medical Officer, Amylin Pharmaceuticals

Orville G. Kolterman, M.D. is the chief medical officer of Whole Biome Inc. Prior to that, Dr. Kolterman joined Amylin in 1992 and served as Senior Vice President, Clinical Affairs and Senior Vice President, Regulatory Affairs until 2012, when the company was acquired by AstraZeneca and Bristol-Myers Squibb. Dr. Kolterman was instrumental in the development of Amylin’s first-in-class diabetes medicines, SYMLIN (pramlintide acetate) injection and BYETTA (exenatide) injection. Prior to Amylin, Dr. Kolterman was Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the UC San Diego Medical Center. He has also served as Assistant Professor of Medicine in the Endocrinology and Metabolism Division at the University of Colorado School of Medicine, Denver and was a member of the Diabetes Control and Complications Trial Study Group. Dr. Kolterman currently serves as a consultant to the Epidemiology of Diabetes Intervention and Complications Study. Dr. Kolterman received his M.D. from Stanford University School of Medicine.

Daniel Pipeleers, M.D., Ph.D.

Daniel Pipeleers, M.D., Ph.D.

Director, Diabetes Research Center, Free University of Brussels, Belgium

Daniel Pipeleers, M.D., Ph.D. is the director of the Diabetes Research Center at the Free University of Brussels. Since 2002, he has been the director of the The Center for Beta Cell Therapy in Diabetes. He founded two networks for clinical translation, the Belgian Diabetes Registry with associated Diabetes Biobank and the international Beta Cell Therapy Consortium, supported by grants from the European Commission and JDRF. Since 1990, he has been the director of the VUB-Diabetes Research Center, where expertise in beta cell biology, pathology, and therapy guides strategies and trials for early diagnosis, prevention, and treatment of type 1 diabetes. Since 1980, he has been a professor at Vrije Universiteit Brussel-VUB and since 1987, a consultant at University Hospital, Brussels. Between 1971 and 1980, he was an investigator at the Belgian Research Foundation and Harkness Fellow Commonwealth Foundation at Université Libre de Bruxelles, Washington University St Louis, Queen Elisabeth Foundation Brussels. Dr. Pipeleers is an Honorary Doctor at Uppsala University, Sweden, member of the Belgian Royal Academy of Medicine, recipient of twelve international and national awards in medical sciences. He has served as a board member and advisor in academic, clinical, and governmental institutions in scientific and bioindustrial organizations.

James S. Shapiro, M.D., Ph.D.

James S. Shapiro, M.D., Ph.D.

Director, Clinical Islet and Living Donor Liver Transplant Programs, University of Alberta, Edmonton, Canada

James Shapiro, M.D., Ph.D. is Professor of Surgery, Medicine and Surgical Oncology, and Director of the Clinical Islet and Living Donor Liver Transplant Programs at the University of Alberta in Edmonton, Canada. He directs one of the leading clinical islet transplant programs worldwide with hundreds of patients treated and was the lead investigator of the team that developed the “Edmonton Protocol,” the first trial to achieve consistent 100% insulin independence in islet-alone transplant recipients with type 1 diabetes. Dr. Shapiro subsequently led the trial which replicated these findings in nine international centers. He has an active experimental laboratory working on improving long term survival of transplanted islets and in immunomodulation of transplanted tissues. Dr. Shapiro is fellow of the Royal Society of Canada and has received several prestigious awards, including the Hunterian Medal from the Royal College of Surgeons of England, the Paul E. Lacy Gold Medal, the Gold Medal in Surgery from the Royal College of Physicians and Surgeons of Canada, the Governor General’s Gold Medal, the Queen’s Jubilee Medal, the Meritorious Service Medal. He obtained his M.D. at the University of Newcastle-upon-Tyne and trained in surgery at the University of Bristol, UK.

Jay S. Skyler, M.D.

Jay S. Skyler, M.D.

Professor of Medicine, Pediatrics, and Psychology, University of Miami Miller School of Medicine and Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute

Jay S. Skyler, M.D., MACP, is a professor of Medicine, Pediatrics, and Psychology in the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida. He served as director of that Division from 2000 to 2004. At the University of Miami, he is deputy director for Clinical Research and Academic Programs in the Diabetes Research Institute. For 22 years, Dr. Skyler served as chairman of the NIH (NIDDK)-sponsored Type 1 Diabetes TrialNet, an international network conducting clinical trials to prevent type 1 diabetes or interdict the type 1 diabetes disease process. His research interests are in clinical aspects of diabetes, particularly improving the care of type 1 diabetes through meticulous glycemic control, psychosocial and behavioral support, and immune system intervention. He is widely acclaimed for developing “algorithms” for patient adjustment of insulin doses. Dr. Skyler is a past president of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a vice president of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. He was founding editor-in-chief of Diabetes Care and currently is senior editor of Diabetes Technology & Therapeutics. He has a B.S. from Pennsylvania State University and a M.D. from Jefferson Medical College. He served as an intern, resident, and fellow, and was on the faculty of Duke University.

Sign up for updates

To have our press releases and major updates sent to you, please provide your name and email address.